文献速递妇科生殖医学

甲氨蝶呤治疗复发性与原发性异位妊娠的疗效比较:系统评价与Meta分析

Success of Methotrexate for the Management of Recurrent Compared With Primary Ectopic Pregnancy: A Systematic Review and Meta-analysis.
PubMed 文献 · Obstet Gynecol · 2025-07-17

该系统评价与Meta分析比较了肌内注射甲氨蝶呤在复发性与原发性异位妊娠患者中的疗效,共纳入15项观察性研究、3944例患者(复发性502例,原发性3442例)。单剂量方案在复发性异位妊娠中的成功率显著低于原发性异位妊娠(RR 0.79,95%CI 0.63-1.00,P=.050),而多剂量方案两组成功率无统计学差异(RR 1.14,95%CI 0.71-1.84,P=.590)。

要点

  • 单剂量肌内注射甲氨蝶呤治疗复发性异位妊娠的成功率低于原发性异位妊娠(RR 0.79,95%CI 0.63-1.00,P=.050)。
  • 多剂量肌内注射甲氨蝶呤治疗复发性与原发性异位妊娠的成功率无统计学差异(RR 1.14,95%CI 0.71-1.84,P=.590)。
  • 当前观察性数据提示,复发性异位妊娠患者可考虑采用多剂量肌内注射甲氨蝶呤以取得与原发性异位妊娠相似的成功率。

核心结论

  • 当前观察性数据提示,复发性异位妊娠患者应考虑采用多剂量肌内注射甲氨蝶呤,以达到与原发性异位妊娠相似的成功率。

研究设计与样本

  • 本Meta分析按照PRISMA指南进行,检索MEDLINE、EMBASE和Scopus数据库,检索时间为2025年2月。
  • 纳入标准为英文全文研究,成人患者(18岁及以上)接受肌内注射甲氨蝶呤治疗并按既往异位妊娠史分层。
  • 复发性异位妊娠定义为至少有一次既往异位妊娠,无论累及哪侧输卵管及既往如何处理。
  • 排除未报告需要进一步治疗患者的研究、研究非肌内途径给药或其他疗法的研究、以及研究非输卵管异位妊娠或异位妊娠的研究。
  • 最终纳入15项观察性研究,共3944例患者(复发性502例,原发性异位妊娠3442例)。

主要发现

  • 单剂量肌内注射甲氨蝶呤在复发性异位妊娠患者中的治疗成功率显著低于原发性异位妊娠患者(RR 0.79,95%CI 0.63-1.00,P=.050)。
  • 多剂量(包括两剂和固定多剂量即两剂或以上)肌内注射甲氨蝶呤治疗中,复发性与原发性异位妊娠的成功率无统计学差异(RR 1.14,95%CI 0.71-1.84,P=.590)。

关键数值与推荐

  • 主要结局为治疗成功,定义为异位妊娠完全消退且无需进一步治疗。
  • 评估了单剂量和多剂量(包括两剂和固定多剂量即两剂或以上)肌内注射甲氨蝶呤方案的疗效。
  • 结局以相对危险度(RR)和95%CI报告。

临床怎么用

  • 作者认为,复发性异位妊娠患者应考虑采用多剂量肌内注射甲氨蝶呤,以达到与原发性异位妊娠相似的成功率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the efficacy of intramuscular (IM) methotrexate in patients with recurrent compared with primary ectopic pregnancy. DATA SOURCES: Systematic searches of the MEDLINE, EMBASE, and Scopus databases were conducted in February 2025. METHODS OF STUDY SELECTION: This meta-analysis was conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. All English-language, full-text studies in which adult patients (18 years of age or older) were treated with IM methotrexate and stratified by their history of a previous ectopic pregnancy were included. Patients with at least one prior ectopic pregnancy, regardless of which fallopian tube was affected and how it was managed, were defined as having recurrent ectopic pregnancy . We excluded studies that did not report patients requiring further treatment, those in which medical management through alternative routes (other than IM) or therapies were studied, and those investigating nontubal ectopic pregnancy or heterotopic pregnancies. TABULATION, INTEGRATION, AND RESULTS: Two investigators independently identified studies using the eligibility criteria. The primary outcome was treatment success, characterized by the complete resolution of ectopic pregnancy without the need for further treatment. The efficacy of single-dose and multidose (comprising both two doses and fixed multidose, ie, two or more doses) IM methotrexate regimens was evaluated. Outcomes were reported as relative risk (RR) and 95% CI. From 6,349 search results, 15 observational studies comprising 3,944 patients (502 recurrent, 3,442 primary ectopic pregnancy) were included. Administration of a single dose of IM methotrexate was significantly less successful in patients with recurrent compared with those with primary ectopic pregnancy (RR 0.79, 95% CI, 0.63-1.00, P =.050). However, there was no statistical difference in success for patients receiving multidose treatment (RR 1.14, 95% CI, 0.71-1.84, P =.590). CONCLUSION: Current observational data suggest that patients with recurrent ectopic pregnancy should be considered for multidose IM methotrexate to achieve similar rates of success compared with primary ectopic pregnancy. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42025642895.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Bhat S, Bhat S, Sircar S, et al. Success of Methotrexate for the Management of Recurrent Compared With Primary Ectopic Pregnancy: A Systematic Review and Meta-analysis. Obstet Gynecol. 2025. PMID: 40674737. doi:10.1097/AOG.0000000000006013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。